Topoisomerase IIα as a prognostic factor in mantle cell lymphoma

Leukemia

Volumn 18, Issue 8, 2004, Pages 1347-1349

  Korkolopoulou, P ^a,b   Vassilakopoulos, T P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUDARABINE; KI 67 ANTIGEN; MITOXANTRONE; PREDNISONE; RETINOBLASTOMA PROTEIN; RITUXIMAB; VINBLASTINE; VINCRISTINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PHASE; CELL PROLIFERATION; DNA CLEAVAGE; DRUG RESPONSE; ENZYME PHOSPHORYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; CELL DIVISION; ENZYMOLOGY; NOTE; PREDICTION AND FORECASTING; SURVIVAL RATE;

ANTIGENS, NEOPLASM; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 4344575939     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403413     Document Type: Article

References (25)

1. Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D et al. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004; 18: 1200-1206.
2. Swerdlow SH, Berger F, Isaackson PI, Müller-Hermelink HK, Nathwani BN, Piris MA et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Pathology and Genetics. Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001, pp 168-170.
3. Anon. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
4. Lenz G, Dreyling M, Hiddeman W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 71-77.
5. Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-262.
6. 2-microglobulin and the tumor score. Cancer 2003; 98: 2630-2635.
7. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
8. Andersen NS, Jensen MK, de Nully Brown P, Geisler CH. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002; 38: 401-408.
9. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA et al. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
10. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12: 1281-1287.
11. Oinonen R, Fransilla K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998; 34: 329-336.
12. Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-262.
13. H genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975-4981.
14. Angelopoulou MK, Siakantaris MP, Vassilakopoulos TP, Kontopidou FN, Rassidakis G, Dimopoulou MN et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002; 68: 12-21.
15. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115-127.
16. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302-4310.
17. Pinyol M, Hernandez L, Cazorla M, Balbin M, Jares P, Fernandez PL et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphoma. Blood 1997; 89: 272-280.
18. Korkolopoulou P, Angelopoulou M, Siakantari M, Mitropoulos F, Vassilakopoulos T, Zorzos H et al. Evaluation of DNA topoisomerase II expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology 2001; 38: 45-53.
19. Provencio M, Corbacho C, Salas C, Millan I, Espana P, Bonilla F et al. The topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 1406-1411.
20. Vassilakopoulos TP, Doussis-Anagnostopoulou I, Angelopoulou MK, Siakantaris MP, Kittas C, Pangalis GA. Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Topoisomerase IIa expression in Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 5430-5431.
21. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517-530.
22. Järvinen TAH, Holli K, Kuukasjärvi T, Isola JJ. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-2273.
23. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle-cell lymphoma. Cancer Cell 2003; 3: 185-197.
24. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619-626.
25. Letestu R, Ugo V, Valensi F, Radford-Weiss I, Nataf J, Levy V et al. Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia 2004; 18: 953-961.